CompletedPhase 1NCT00977431

Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform

Studying Glioblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Boehringer Ingelheim
Principal Investigator
Boehringer Ingelheim
Boehringer Ingelheim
Intervention
Temozolomide(drug)
Enrollment
36 enrolled
Eligibility
18-69 years · All sexes
Timeline
2009 – 2017

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00977431 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma →

← Back to all trials